In GBM, functions of MIF include enhancement of CSC maintenance (39, 40), resistance to therapies including SOC chemotherapy temozolomide (41) and the antiangiogenic agent bevacizumab (42), and alteration of growth factor receptor signaling (34). This evidence concerns the gene MIF and glioblastoma.